About Incyte

Incyte discovers, develops and commercialises therapies across three critical disease areas: Hematology, Oncology and Inflammation and Autoimmunity. With nine approved products and dozens of ongoing clinical trials, the company transforms science into medicines that address complex conditions where few options exist. Its research teams pursue molecular targets and novel compounds designed to change outcomes for patients facing serious illness. Operating globally with more than 2,800 employees across North America, Europe and Asia, Incyte has built a robust pipeline since starting with a small group of scientists in 2002. Recognised as a top employer in science for eight consecutive years, the company centres on one principle: patients are waiting, and every advancement matters.